IP Library Granted Patent US 8,771,693
Granted Patent B2
US 8,771,693 · App. 13/504,700 · Granted Jul 8, 2014

Methods and compositions for the generation and use of conformation-specific antibodies

Inventors: Kun Ping Lu (Newton, MA); Xiao Zhen Zhou (Newton, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,771,693
App. No.
13/504,700
Granted
Jul 8, 2014
Kind
B2
Abstract

The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof.

Claims (28)

1. An isolated conformation-specific antibody or fragment thereof that specifically binds to a Xaa-Pro motif of a polypeptide, wherein: said polypeptide is a PPlase substrate, the peptidyl-prolyl bond of said Xaa-Pro motif is in a cis conformation, said Xaa is serine or threonine and is phosphorylated, and said antibody or fragment thereof binds to the cis conformation of said Xaa-Pro motif of said polypeptide with at least 10- to 100-fold greater affinity than to the trans conformation of said Xaa-Pro motif of said polypeptide.

2. The isolated antibody of claim 1 , wherein said PPlase substrate is a Pin1 substrate.

3. The isolated antibody of claim 2 , wherein said Pin1 substrate is NIMA, RAB4, CDC25, WEE1, PLK1, MYT1, CDC27, CENP-F, Incenp, RBP1, NHERF-1, KRMP1, CK2, TopoIIα, DAB2, p54nrb, Sil, EMI1, cyclin D1, Ki67, c-Myc, cyclin E, c-Jun, β-catenin, Cf-2, NF-κB, RAF1, c-Fos, RARα, AIB1/SRC-3, HBx, STAT3, p53, Bcl-2, p73, BimEL, p66Shc, CHE1, tau, amyloid precursor protein (APP), APP fragment, synphilin-1, gephyrin, MCL1, NFAT, AUF1, IRF3, BTK, SIN3-RPD3, or hSpt5.

4. The isolated antibody of claim 1 , produced by a process which comprises the steps of:

(i) providing an antibody library;

(ii) contacting said antibody library with a polypeptide comprising a Xaa-Pro motif;

(iii) determining binding of an antibody from said antibody library to said Xaa-Pro motif of said polypeptide, wherein said antibody specifically binds to the cis conformation of said Xaa-Pro motif of said polypeptide; and

(iv) isolating said antibody, wherein said antibody is a conformation-specific antibody.

5. An isolated antibody composition of claim 1 to induce passive immunity against a disorder associated with a deregulation of PPlase activity.

6. The isolated antibody of claim 3 , wherein said Pin1 substrate is tau.

7. The isolated antibody of claim 3 , wherein said Pin1 substrate is APP.

8. The isolated antibody of claim 3 , wherein said Pin1 substrate is c-Jun.

9. The isolated antibody of claim 3 , wherein said Pin1 substrate is NF-κB.

10. The isolated antibody of claim 3 , wherein said Pin1 substrate is p53.

11. An isolated conformation-specific antibody or fragment thereof that specifically binds to a Xaa-Pro motif of a polypeptide, wherein: said polypeptide is a PPlase substrate, the peptidyl-prolyl bond of said Xaa-Pro motif is in a trans conformation, said Xaa is serine or threonine and is phosphorylated, and said antibody or fragment thereof binds to the trans conformation of said Xaa-Pro motif of said polypeptide with at least 10- to 100-fold greater affinity than to the cis conformation of said Xaa-Pro motif of said polypeptide.

12. The isolated antibody of claim 11 , wherein said PPlase substrate is a Pin1 substrate.

13. The isolated antibody of claim 12 , wherein said Pin1 substrate is NIMA, RAB4, CDC25, WEE1, PLK1, MYT1, CDC27, CENP-F, Incenp, RBP1, NHERF-1, KRMP1, CK2, TopoIIα, DAB2, p54nrb, Sil, EMI1, cyclin D1, Ki67, c-Myc, cyclin E, c-Jun, β-catenin, Cf-2, NF-κB, RAF1, c-Fos, RARα, AIB1/SRC-3, HBx, STAT3, p53, Bcl-2, p73, BimEL, p66Shc, CHE1, tau, amyloid precursor protein (APP), APP fragment, synphilin-1, gephyrin, MCL1, NFAT, AUF1, IRF3, BTK, SIN3-RPD3, or hSpt5.

14. The isolated antibody of claim 13 , wherein said Pin1 substrate is tau.

15. The isolated antibody of claim 13 , wherein said Pin1 substrate is APP.

16. The isolated antibody of claim 13 , wherein said Pin1 substrate is c-Jun.

17. The isolated antibody of claim 13 , wherein said Pin1 substrate is NF-κB.

18. The isolated antibody of claim 13 , wherein said Pin1 substrate is p53.

19. The isolated antibody of claim 11 , produced by a process which comprises the steps of:

(i) providing an antibody library;

(ii) contacting said antibody library with a polypeptide comprising a Xaa-Pro motif;

(iii) determining binding of an antibody from said antibody library to said Xaa-Pro motif of said polypeptide, wherein said antibody specifically binds to the trans conformation of said Xaa-Pro motif of said polypeptide; and

(iv) isolating said antibody, wherein said antibody is a conformation-specific antibody.

20. An isolated antibody composition of claim 11 to induce passive immunity against a disorder associated with a deregulation of PPlase activity.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 29, 2016
From: BETH ISRAEL DEACONESS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039508/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2014
From: LU, KUN PING; ZHOU, XIAO ZHEN
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 032957/0222 →
Continuity (2)
Provisional Application 61255341 · Oct 27, 2009
Related Publication 20130028900A1 · Jan 31, 2013